05.12.14
Richard (Rick) A. Rudick, M.D., has been appointed vice president of Development Sciences, Value-Based Medicine, at Biogen Idec. He reports to Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer.
Dr. Rudick will lead the newly created Value-Based Medicine Group that focuses on using new technology to develop innovative programs and tools to better understand, measure and manage the treatment of multiple sclerosis (MS). The group emphasizes more evidence-based, individualized treatment options with the goal of improving care.
Dr. Rudick has played key roles in several MS clinical trials, including the trials of Biogen’s products AVONEX (interferon beta-1a) and TYSABRI (natalizumab). Dr. Rudick joins the company from the Cleveland Clinic, where he served as director of the Mellen Center for Multiple Sclerosis Treatment and Research for nearly 30 years.
“Rick has been a valued partner of the company for more than two decades. Through his years of hands-on clinical experience, he has gained a truly unique understanding of the needs of MS patients,” said Dr. Sandrock. “His vision, expertise and passion bolsters our efforts to create real-world, practical solutions to empower better decision-making and improve the way people live with MS.”
Dr. Rudick will lead the newly created Value-Based Medicine Group that focuses on using new technology to develop innovative programs and tools to better understand, measure and manage the treatment of multiple sclerosis (MS). The group emphasizes more evidence-based, individualized treatment options with the goal of improving care.
Dr. Rudick has played key roles in several MS clinical trials, including the trials of Biogen’s products AVONEX (interferon beta-1a) and TYSABRI (natalizumab). Dr. Rudick joins the company from the Cleveland Clinic, where he served as director of the Mellen Center for Multiple Sclerosis Treatment and Research for nearly 30 years.
“Rick has been a valued partner of the company for more than two decades. Through his years of hands-on clinical experience, he has gained a truly unique understanding of the needs of MS patients,” said Dr. Sandrock. “His vision, expertise and passion bolsters our efforts to create real-world, practical solutions to empower better decision-making and improve the way people live with MS.”